Here's Eli Lilly's Competitive Advantage in GLP-1 Obesity Drugs and Abbott's Supporting Role

Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the final hour of trading on Wall Street. (We will no longer be recording audio, so we can get this new written feature to members as quickly as possible.)

scroll to top